CPIX
NASDAQ · Pharmaceuticals
Cumberland Pharmaceuticals
$7.37
+0.05 (+0.68%)
Financial Highlights (FY 2026)
Revenue
43.97M
Net Income
-2,800,686
Gross Margin
85.0%
Profit Margin
-6.4%
Rev Growth
+2.0%
D/E Ratio
0.21
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 85.0% | 85.0% | 36.5% | 36.5% |
| Operating Margin | -6.3% | -5.6% | 16.5% | 18.3% |
| Profit Margin | -6.4% | -6.1% | 15.4% | 17.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 43.97M | 43.13M | 7.91M | 6.82M |
| Gross Profit | 37.38M | 36.67M | 2.89M | 2.49M |
| Operating Income | -2,756,939 | -2,433,786 | 1.31M | 1.25M |
| Net Income | -2,800,686 | -2,472,405 | 1.22M | 1.20M |
| Gross Margin | 85.0% | 85.0% | 36.5% | 36.5% |
| Operating Margin | -6.3% | -5.6% | 16.5% | 18.3% |
| Profit Margin | -6.4% | -6.1% | 15.4% | 17.6% |
| Rev Growth | +2.0% | +2.0% | +3.2% | +18.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 9.19M | 9.19M | 24.05M | 29.86M |
| Total Equity | 43.63M | 43.63M | 36.32M | 43.10M |
| D/E Ratio | 0.21 | 0.21 | 0.66 | 0.69 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 1.34M | 1.25M | 2.16M | 1.75M |
| Free Cash Flow | — | — | 556.1K | 718.5K |